SLC45A3 is altered in 0.20% of all cancers with prostate adenocarcinoma, pancreatic adenocarcinoma, lung adenocarcinoma, adenocarcinoma of the gastroesophageal junction, and breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in SLC45A3 are SLC45A3-BRAF Fusion (0.06%), SLC45A3-FGFR2 Fusion (0.16%), SLC45A3-ERG Fusion (0.03%), SLC45A3 L223_A234del (2.43%), and SLC45A3-ETV1 Fusion (0.03%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.